Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > FGA(Gene name) > Human
  • Add your favorite
  • FGA (Gene name),
  • Fibrinogen alpha chain (Protein name ),  FIBA_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Citations  (5)
  • |
  • Feedback
  • Gene name:
    FGA;
    Protein name:
    Fibrinogen alpha chain;
    Alternative:

    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    Heterohexamer; disulfide linked. Contains 2 sets of 3 non-identical chains (alpha, beta and gamma). The 2 heterotrimers are in head to head conformation with the N-termini in a small central domain.
    Function:
    Fibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.
    Subcellular Location:
    Secreted
    Protein Attributes:
    Sequence length:
    866
    Sequence:
    50:
    MFSMRIVCLV | LSVVGTAWTA | DSGEGDFLAE | GGGVRGPRVV | ERHQSACKDS | 
    100:
    DWPFCSDEDW | NYKCPSGCRM | KGLIDEVNQD | FTNRINKLKN | SLFEYQKNNK | 
    150:
    DSHSLTTNIM | EILRGDFSSA | NNRDNTYNRV | SEDLRSRIEV | LKRKVIEKVQ | 
    200:
    HIQLLQKNVR | AQLVDMKRLE | VDIDIKIRSC | RGSCSRALAR | EVDLKDYEDQ | 
    250:
    QKQLEQVIAK | DLLPSRDRQH | LPLIKMKPVP | DLVPGNFKSQ | LQKVPPEWKA | 
    300:
    LTDMPQMRME | LERPGGNEIT | RGGSTSYGTG | SETESPRNPS | SAGSWNSGSS | 
    350:
    GPGSTGNRNP | GSSGTGGTAT | WKPGSSGPGS | TGSWNSGSSG | TGSTGNQNPG | 
    400:
    SPRPGSTGTW | NPGSSERGSA | GHWTSESSVS | GSTGQWHSES | GSFRPDSPGS | 
    450:
    GNARPNNPDW | GTFEEVSGNV | SPGTRREYHT | EKLVTSKGDK | ELRTGKEKVT | 
    500:
    SGSTTTTRRS | CSKTVTKTVI | GPDGHKEVTK | EVVTSEDGSD | CPEAMDLGTL | 
    550:
    SGIGTLDGFR | HRHPDEAAFF | DTASTGKTFP | GFFSPMLGEF | VSETESRGSE | 
    600:
    SGIFTNTKES | SSHHPGIAEF | PSRGKSSSYS | KQFTSSTSYN | RGDSTFESKS | 
    650:
    YKMADEAGSE | ADHEGTHSTK | RGHAKSRPVR | DCDDVLQTHP | SGTQSGIFNI | 
    700:
    KLPGSSKIFS | VYCDQETSLG | GWLLIQQRMD | GSLNFNRTWQ | DYKRGFGSLN | 
    750:
    DEGEGEFWLG | NDYLHLLTQR | GSVLRVELED | WAGNEAYAEY | HFRVGSEAEG | 
    800:
    YALQVSSYEG | TAGDALIEGS | VEEGAEYTSH | NNMQFSTFDR | DADQWEENCA | 
    850:
    EVYGGGWWYN | NCQAANLNGI | YYPGGSYDPR | NNSPYEIENG | VVWVSFRGAD | 
    866:
    YSLRAVRMKI | RPLVTQ
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    Pfam:
    SMR:
    MIM:
    KEGG:
    UniGene:
    String:
    Uniprot:
     
    FOR
    ELISA Kit for Human Fibrinogen alpha chain
    ELISA Kit for Human Fibrinogen alpha chain
    ELISA Kit for Human Fibrinogen alpha chain
    ELISA Kit for Human Fibrinogen alpha chain
    ELISA Kit for Human Fibrinogen alpha chain
    ELISA Kit for Human Fibrinogen alpha chain
    ELISA Kit for Human Fibrinogen alpha chain
    CLIA Kit for Human Fibrinogen alpha chain
    CLIA Kit for Human Fibrinogen alpha chain
    CLIA Kit for Human Fibrinogen alpha chain
    CLIA Kit for Human Fibrinogen alpha chain
    CLIA Kit for Human Fibrinogen alpha chain
    CLIA Kit for Human Fibrinogen alpha chain
    CLIA Kit for Human Fibrinogen alpha chain
    Polyclonal Antibody for Human Fibrinogen alpha chain
    Polyclonal Antibody for Human Fibrinogen alpha chain
    Polyclonal Antibody for Human Fibrinogen alpha chain
    Polyclonal Antibody for Human Fibrinogen alpha chain
    Polyclonal Antibody for Human Fibrinogen alpha chain
    Polyclonal Antibody for Human Fibrinogen alpha chain
    Polyclonal Antibody for Human Fibrinogen alpha chain
    Monoclonal Antibody for Human Fibrinogen alpha chain
    Monoclonal Antibody for Human Fibrinogen alpha chain
    Monoclonal Antibody for Human Fibrinogen alpha chain
    Monoclonal Antibody for Human Fibrinogen alpha chain
    Monoclonal Antibody for Human Fibrinogen alpha chain
    Monoclonal Antibody for Human Fibrinogen alpha chain
    Monoclonal Antibody for Human Fibrinogen alpha chain
    Protein for Human Fibrinogen alpha chain
    Protein for Human Fibrinogen alpha chain
    Protein for Human Fibrinogen alpha chain
    Protein for Human Fibrinogen alpha chain
    Protein for Human Fibrinogen alpha chain
    Protein for Human Fibrinogen alpha chain
    Protein for Human Fibrinogen alpha chain

    R&D Technical Data
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    s

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤9.1%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤12.4%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    Recovery was determined by spiking various levels of FIBA into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    105

    96-108

    Plasma

    104

    100-106

     

     

     

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of FIBA and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

     

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    102-110%

    104-112%

    98-106%

    96-106%

    EDTA plasma(n=5)

    103-108%

    96-105%

    98-107%

    102-108%

    heparin plasma(n=5)

    95-110%

     

    96-102%

    101-106%

    105-109%

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    References
    1. 1.
      "Localization of the alpha-chain cross-link acceptor sites of human fibrin."
      Fretto L.J. , Ferguson E.W. , Steinman H.M. , McKee P.A.
      J. Biol. Chem.253:2184-2195(1978) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CROSS-LINKING ACCEPTOR SITES
    2. 2.
      "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry."
      Liu T. , Qian W.-J. , Gritsenko M.A. , Camp D.G. II , Monroe M.E. , Moore R.J. , Smith R.D.
      J. Proteome Res.4:2070-2080(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-686
      tissue: Plasma.
    3. 3.
      "Disulfide bridges in NH2-terminal part of human fibrinogen."
      Blombaeck B. , Hessel B. , Hogg D.
      Thromb. Res.8:639-658(1976) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: DISULFIDE BONDS
    4. 4.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: REVIEW;ELECTRON MICROSCOPY;POLYMERIZATION;LIGANDS
    5. 5.
      "Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor."
      Kimura S. , Aoki N.
      J. Biol. Chem.261:15591-15595(1986) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CROSS-LINKING SITE FOR ALPHA-2-PLASMIN INHIBITOR
    6. 6.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION
    7. 7.
      "Phosphoproteomic analysis of the human pituitary."
      Beranova-Giorgianni S. , Zhao Y. , Desiderio D.M. , Giorgianni F.
      Pituitary9:109-120(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
      tissue: Pituitary.
    8. 8.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-412 AND SER-609;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
      tissue: Platelet.
    9. 9.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: HYDROXYLATION AT PRO-565
    10. 10.
      "Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry."
      Chen R. , Jiang X. , Sun D. , Han G. , Wang F. , Ye M. , Wang L. , Zou H.
      J. Proteome Res.8:651-661(2009) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-686
      tissue: Liver.
    11. 11.
      "A unique proteolytic fragment of human fibrinogen containing the A alpha COOH-terminal domain of the native molecule."
      Kirschbaum N.E. , Budzynski A.Z.
      J. Biol. Chem.265:13669-13676(1990) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CLEAVAGE BY HEMENTIN AND PLASMIN
    12. 12.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
    13. 13.
      "Glycoproteomic analysis of human fibrinogen reveals novel regions of O-glycosylation."
      Zauner G. , Hoffmann M. , Rapp E. , Koeleman C.A. , Dragan I. , Deelder A.M. , Wuhrer M. , Hensbergen P.J.
      J. Proteome Res.11:5804-5814(2012) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: GLYCOSYLATION AT THR-320 AND SER-351
    14. 14.
      "Characterization of fibrinogen glycosylation and its importance for serum/plasma N-glycome analysis."
      Adamczyk B. , Struwe W.B. , Ercan A. , Nigrovic P.A. , Rudd P.M.
      J. Proteome Res.12:444-454(2013) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: LACK OF GLYCOSYLATION
    15. 15.
      "The structure of residues 7-16 of the A alpha-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution."
      Martin P.D. , Robertson W. , Turk D. , Huber R. , Bode W. , Edwards B.F.P.
      J. Biol. Chem.267:7911-7920(1992) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-39
    16. 16.
      "Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin."
      Spraggon G. , Everse S.J. , Doolittle R.F.
      Nature389:455-462(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 130-216
    17. 17.
      "Crystal structure of fragment double-D from human fibrin with two different bound ligands."
      Everse S.J. , Spraggon G. , Veerapandian L. , Riley M. , Doolittle R.F.
      Biochemistry37:8637-8642(1998) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 130-216
    18. 18.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 666-866;GLYCOSYLATION AT ASN-686
    19. 19.
      "Conformational changes in fragments D and double-D from human fibrin(ogen) upon binding the peptide ligand Gly-His-Arg-Pro-amide."
      Everse S.J. , Spraggon G. , Veerapandian L. , Doolittle R.F.
      Biochemistry38:2941-2946(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 130-216
    20. 20.
      "Fibrinogen Kyoto II, a new congenitally abnormal molecule, characterized by the replacement of A alpha proline-18 by leucine."
      Yoshida N. , Okuma M. , Hirata H. , Matsuda M. , Yamazumi K. , Asakura S.
      Blood78:149-153(1991) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT KYOTO-2 LEU-37
    21. 21.
      "Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator."
      Maekawa H. , Yamazumi K. , Muramatsu S. , Kaneko M. , Hirata H. , Takahashi N. , Arocha-Pinango C.L. , Rodriguez S. , Nagy H. , Perez-Requejo J.L. , Matsuda M.
      J. Clin. Invest.90:67-76(1992) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT LIMA SER-160
    22. 22.
      "An A alpha Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation."
      Maekawa H. , Yamazumi K. , Muramatsu S. , Kaneko M. , Hirata H. , Takahashi N. , de Bosch N.B. , Carvajal Z. , Ojeda A. , Arocha-Pinango C.L. , Matsuda M.
      J. Biol. Chem.266:11575-11581(1991) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT CARACAS-2 ASN-453
    23. 23.
      "Molecular basis for fibrinogen Dusart (A alpha 554 Arg-->Cys) and its association with abnormal fibrin polymerization and thrombophilia."
      Koopman J. , Haverkate F. , Grimbergen J. , Lord S.T. , Mosesson M.W. , Diorio J.P. , Siebenlist K.S. , Legrand C. , Soria J. , Soria C. , Caen J.P.
      J. Clin. Invest.91:1637-1643(1993) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT DUSART/PARIS-5 CYS-573
    24. 24.
      "Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain."
      Benson M.D. , Liepnieks J. , Uemichi T. , Wheeler G. , Correa R.
      Nat. Genet.3:252-255(1993) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT AMYL8 LEU-573
    25. 25.
      "Fibrinogen Osaka IV: a congenital dysfibrinogenemia found in a patient originally reported in relation to surgery, now defined to have an A alpha arginine-16 to histidine substitution."
      Yamazumi K. , Terukina S. , Matsuda M. , Kanbayashi J. , Sakon M. , Tsujinaka T.
      Surg. Today23:45-50(1993) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT OSAKA IV HIS-35
    26. 26.
      "Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A-alpha 20 Val-to-Asp)."
      Brennan S.O. , Hammonds B. , George P.M.
      J. Clin. Invest.96:2854-2858(1995) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT CANTERBURY ASP-39
    27. 27.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS ALA-331 AND GLU-446
    28. 28.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: ERRATUM
    29. 29.
      "Carboxy-terminal-extended variant of the human fibrinogen alpha subunit: a novel exon conferring marked homology to beta and gamma subunits."
      Fu Y. , Weissbach L. , Plant P.W. , Oddoux C. , Cao Y. , Liang T.J. , Roy S.N. , Redman C.M. , Grieninger G.
      Biochemistry31:11968-11972(1992) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA];ALTERNATIVE SPLICING (ISOFORMS 1 AND 2)
    30. 30.
      "Fibrinogen DNA and protein sequences."
      Chung D.W. , Grieninger G.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE (ISOFORM 1)
    31. 31.
      SeattleSNPs variation discovery resource
      Submitted (2001-06) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA];VARIANTS VAL-6; ALA-331 AND ALA-456
    32. 32.
      "Complete sequencing and characterization of 21,243 full-length human cDNAs."
      Ota T. , Suzuki Y. , Nishikawa T. , Otsuki T. , Sugiyama T. , Irie R. , Wakamatsu A. , Hayashi K. , Sato H. , Nagai K. , Kimura K. , Makita H. , Sekine M. , Obayashi M. , Nishi T. , Shibahara T. , Tanaka T. , Ishii S. , more...
      Nat. Genet.36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2);VARIANT ALA-331
      tissue: Heart.
    33. 33.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    34. 34.
      "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
      The MGC Project Team
      Genome Res.14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2)
    35. 35.
      "Nucleotide sequences of the three genes coding for human fibrinogen."
      Chung D.W. , Harris J.E. , Davie E.W.
      Adv. Exp. Med. Biol.281:39-48(1990) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE OF 1-655 (ISOFORM 1)
      tissue: Liver.
    36. 36.
      "Partial mRNA sequences for human A alpha, B beta, and gamma fibrinogen chains: evolutionary and functional implications."
      Kant J.A. , Lord S.T. , Crabtree G.R.
      Proc. Natl. Acad. Sci. U.S.A.80:3953-3957(1983) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2)
    37. 37.
      "Characterization of a complementary deoxyribonucleic acid coding for the alpha chain of human fibrinogen."
      Rixon M.W. , Chan W.-Y. , Davie E.W. , Chung D.W.
      Biochemistry22:3237-3244(1983) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 1-629
    38. 38.
      "Human fibrinogen: sequence, sulfur bridges, glycosylation and some structural variants."
      Henschen A. , Lottspeich F. , Southan C. , Topfer-Petersen E.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PROTEIN SEQUENCE OF 20-629
    39. 39.
      "Amino acid sequence studies on the alpha chain of human fibrinogen. Overlapping sequences providing the complete sequence."
      Watt K.W.K. , Cottrell B.A. , Strong D.D. , Doolittle R.F.
      Biochemistry18:5410-5416(1979) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PROTEIN SEQUENCE OF 20-629;DISULFIDE BONDS
    40. 40.
      "Isolation and characterisation of cDNA clones for the A alpha- and gamma-chains of human fibrinogen."
      Imam A.M.A. , Eaton M.A.W. , Williamson R. , Humphries S.
      Nucleic Acids Res.11:7427-7434(1983) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 110-156
    41. 41.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE OF 605-644 (ISOFORM 2)
    42. 42.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PROTEIN SEQUENCE OF 20-35
    43. 43.
      "Amino acid sequence studies on the alpha chain of human fibrinogen. Exact location of cross-linking acceptor sites."
      Cottrell B.A. , Strong D.D. , Watt K.W.K. , Doolittle R.F.
      Biochemistry18:5405-5410(1979) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CROSS-LINKING ACCEPTOR SITES
    Product Feedback Wall
    Hot Genes
    Atf2 ASPRO ACE ALCAM C19orf80 Trap1a KSR2 Gdf5
    Top Searches
    Ubiquitin-protein ligase Ubiquitin ELISA metalloproteinase Tumor necrosis Asprosin TRAP1A Alpha
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    Twitter